Drug repurposing to identify compounds for bipolar disorder treatment – TreatBD
Bipolar disorder (BD) is a psychiatric condition characterized by depressive and manic episodes, for which diagnosis and treatment are challenging and can take several years after the first symptoms. Only 30% of the patients respond to lithium monotherapy with complete disappearance of symptoms, 10-20% do not respond at all and the others show a partial response and are usually treated with complex polypharmacy. Therefore, finding new treatments is pressing. The induced pluripotent stem cell (iPSC) technology provides a unique tool for high-throughput screenings of therapeutic compounds. We discovered a new target in neurons differentiated from iPSC-derived from BD patients that do not respond to lithium that is suitable and meaningful for a drug repurposing approach. This international project gathers three teams expert in iPSC disease modeling, in vivo studies and drug repurposing to successfully take this new BD target into preclinical animal trials of new therapeutic compounds.
Madame Renata SANTOS (Institut national de la sante et de la recherche medicale)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
CENTRE D' ETUDE DES CELLULES SOUCHES
IPNP Institut national de la sante et de la recherche medicale
Help of the ANR 622,034 euros
Beginning and duration of the scientific project: September 2022 - 48 Months